Marea Therapeutics Announces Publication in The Lancet of Positive Data from Phase 2a Clinical Trial of MAR001 for Cardiovascular Disease
Publication follows late-breaking oral presentation of Phase 2a results at the 93rd EAS Congress; MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks
Second publication of MAR001 preclinical results in eBioMedicine that demonstrate improved plasma lipid profiles
SOUTH SAN FRANCISCO, Calif., May 16, 2025--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that positive results from a Phase 2a clinical trial of MAR001 were published in The Lancet entitled "Safety and efficacy of a novel ANGPTL4 inhibitory antibody for lipid lowering: results from phase 1 and phase 1b/2a clinical studies." The publication follows a recent late-breaking oral presentation of the Phase 2a results at the 93rd EAS Congress and can be accessed here. In addition, Marea announced a publication of MAR001 preclinical results in the peer-reviewed journal eBioMedicine entitled "A Novel ANGPTL4 Inhibitory Antibody Safely Improves Lipid Profiles in Non-Human Primates." The publication can be accessed here.
MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. Results from Marea's Phase 2a clinical trial of MAR001 demonstrated approximately 53% placebo-adjusted mean reductions in remnant cholesterol and triglycerides at 12 weeks with a favorable safety profile.
"We are excited to have our MAR001 Phase 2a clinical results and preclinical data recognized within the broader scientific community through these publications in The Lancet and eBioMedicine," said Ethan Weiss, M.D., chief scientific officer of Marea. "These findings validate ANGPTL4 inhibition and the ability of MAR001 to safely and effectively reduce remnant cholesterol and triglycerides, which align with genetic findings and support further development in addressing atherosclerotic cardiovascular disease risk. We look forward to initiating a Phase 2b trial of MAR001 in the second quarter of 2025."
About Remnant Cholesterol
Remnant cholesterol is carried by triglyceride-rich lipoproteins, is highly atherogenic, and drives cardiovascular events independent of classical risk factors like LDL cholesterol, diabetes, or obesity. There are currently no available targeted therapies to lower remnant cholesterol and improve metabolic function.
About MAR001
MAR001 is a first-in-class monoclonal antibody that targets ANGPTL4, a protein that is highly expressed in adipose tissue. By inhibiting ANGPTL4 and thereby augmenting lipoprotein lipase (LPL) activity, MAR001 is designed to lower remnant cholesterol and improve adipose tissue function. Human genetic data has identified ANGPTL4 as a highly promising therapeutic target because loss of function alleles lead to lower remnant cholesterol, improved adipose distribution, improved insulin sensitivity, lower triglyceride levels, and protection from cardiovascular disease and type 2 diabetes.
MAR001 is being developed to reduce the risk of major adverse cardiovascular events (MACE) in adults with established atherosclerotic cardiovascular disease (ASCVD) plus elevated triglycerides and remnant cholesterol.
Preclinical models with MAR001 demonstrated reduction in triglycerides, remnant cholesterol and ectopic fat, and improved insulin sensitivity. Results from a Phase 2a study of MAR001 demonstrated clinically meaningful reductions in remnant cholesterol and triglycerides. Marea plans to advance MAR001 into Phase 2b clinical development in the second quarter of 2025.
About Marea Therapeutics
Marea Therapeutics is a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases. The company's lead therapy, MAR001, is in Phase 2 clinical development for adults with metabolic dysfunction and high risk for cardiovascular disease. The company is also advancing MAR002 for the treatment of acromegaly. To learn more, please visit www.mareatx.com and follow us on LinkedIn and X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250516110509/en/
Contacts
Media Contact:Katie Engleman, 1ABkatie@1abmedia.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 hours ago
- Yahoo
These 7 Everyday Household Items Could Increase Your Risk Of Health Issues, Including Heart Disease
A new study suggests hundreds of thousands of deaths globally are linked to a certain phthalate chemical exposure (DEHP) in plastics. Specifically, they've been linked to cardiovascular-related deaths. DEHP is a type of phthalate, that is commonly added to plastics to make them more flexible. Here are some products where you might find them at home. Research has consistently shown that we should be wary of plastics—and that also goes for the chemicals used to make them, like phthalates. And while it's nearly impossible to fully avoid plastics in your day-to-day, a new study suggests you might want to try a little harder to limit how much you interact with the material, because it has been linked with serious heart issues. The study, which was published in the journal eBioMedicine, linked a specific type of phthalate called di-2-ethylhexylphthalate (DEHP) to cardiovascular-related deaths. Phthalates have been associated with a slew of other serious health complications, including endocrine disruption and fertility issues, by the way. Here's what the latest study found, plus what doctors recommend doing with this info. Meet the experts: Jamie Alan, PhD, an associate professor of pharmacology and toxicology at Michigan State University. Yu-Ming Ni, MD, cardiologist and lipidologist at MemorialCare Heart and Vascular Institute at Orange Coast Medical Center in Fountain Valley, CA. Cheng-Han Chen, MD, cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA. Yanting Wang, MD, cardiologist and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. For the study, researchers analyzed data from the Institute for Health Metrics and Evaluation, a global health research center, along with estimates of regional DEHP exposure. The researchers found that, in 2018, an estimated 356,238 deaths globally were linked to DEHP exposure. Those made up nearly 13.5 percent of all cardiovascular deaths in people between the ages of 55 and 64. Of those, 349,113 were linked to people using plastics. People in some areas of the world that have booming plastic industries saw more of an association than others. 'The findings underscore the need for urgent global and local regulatory interventions to [curb] mortality from DEHP exposure,' the researchers wrote in the conclusion. DEHP is a type of phthalate, and it's commonly added to plastics to make them more flexible, according to the Centers for Disease Control and Prevention (CDC). DEHP is a colorless liquid that is especially prevalent in vinyl materials, which may contain up to 40 percent DEHP, per the CDC. DEHP can also be found in a bunch of common goods you interact with regularly, including certain types of flooring, wall coverings, and even your shoes. It's important to note that the study is observational, meaning it didn't find that exposure to phthalates actually caused these cardiovascular deaths. Instead, it just found a link. 'There may be unknown factors that can explain this rise in death related to phthalates,' says Yu-Ming Ni, MD, cardiologist and lipidologist at MemorialCare Heart and Vascular Institute at Orange Coast Medical Center in Fountain Valley, CA. Still, it's entirely possible that phthalate exposure may raise the risk of cardiovascular disease and death, says Cheng-Han Chen, MD, cardiologist and medical director of the Structural Heart Program at MemorialCare Saddleback Medical Center in Laguna Hills, CA. 'Previous studies have linked phthalates found in plastic to increased inflammation in the bloodstream as well as cardiometabolic disorders such as diabetes and obesity,' he points out. 'These problems could then lead to increased morbidity and mortality from heart disease.' However, Dr. Ni stresses that more research is needed. Some exposure to plastics, phthalates, and DEHP is bound to happen in the world we live in. "As with many chemicals that we are exposed to long-term, it's likely that the totally cumulative exposure over a lifetime is important," says Jamie Alan, PhD, an associate professor of pharmacology and toxicology at Michigan State University. So, she recommends doing that you can to limit your exposure. Experts singled out seven specific items that you should probably try to avoid, if you can: Plastic water bottles. Dr. Ni recommends focusing on reusable containers for liquids, like metal or ceramic water bottles. Certain shampoos. "If you find a phthalate-free shampoo that is affordable and that works, that can decrease exposure," Alan says. Plastic cookware. Putting plastic cookware, like plastic spatulas, in hot items raises the risk that phthalates will end up in your food, per Dr. Ni. Plastic utensils. Putting these products directly into your mouth raises your risk of exposure, Dr. Ni explains. Takeout containers. These are often made with plastic that can leach into your food, per Dr. Ni. Plastic food storage containers. Like plastic takeout containers, these can also result in phthalate exposure for your food, especially if you heat them up, Alan says. Other personal care products. Phthalates show up in a range of personal care products, making it important to look for products like soaps and hairspray without the chemicals, Alan says. (Labels will typically say "phthalate-free.") Of course, this stuff is everywhere, making it hard to avoid entirely. "My best advice is to reduce exposure where it makes sense," Alan says. It's also important to try to cut back on how many plastic products you buy. "Based on the available evidence, it is important we strive to limit the amount of plastic produced and ensure proper disposal for both environmental and biological health," says Yanting Wang, MD, cardiologist and assistant professor of medicine at Rutgers Robert Wood Johnson Medical School. You Might Also Like Jennifer Garner Swears By This Retinol Eye Cream These New Kicks Will Help You Smash Your Cross-Training Goals
Medscape
a day ago
- Medscape
Plasma Biomarker Panel for Early Alzheimer Disease Detection
A fully automated plasma biomarker panel detected amyloid-beta (Aβ) positivity and monitored early amyloid accumulation in middle-aged cognitively unimpaired (CU) adults at risk for Alzheimer's disease. METHODOLOGY: This study involved 400 middle-aged CU individuals at risk for the disease from the Alzheimer's and Families study longitudinal cohort, of whom 135 (median age, 63 years) were Aβ-positive (A+) and 265 (median age, 60.5 years) were Aβ-negative (A−); 54 of 342 participants with PET imaging were PET A+, and assessments were performed every 3 years. Plasma biomarkers — Aβ42/40, p-tau181, glial fibrillary acidic protein, neurofilament light, p-tau217, ApoE4, and p-tau181/Aβ42 and p-tau217/Aβ42 ratios — were quantified via fully automated immunoassays; cerebrospinal fluid (CSF) biomarkers included Aβ42/40, p-tau181, and total tau; MRI assessed cortical thickness, and amyloid PET quantified Aβ deposition. Aβ status was defined using CSF Aβ42/40 ratio (< 0.071) or amyloid PET Centiloid (A+; > 12). Cognitive function was assessed using the modified Preclinical Alzheimer's Cognitive Composite. The primary outcome was the performance of plasma biomarkers in detecting Aβ pathology; secondary outcomes included longitudinal associations between biomarkers and changes in Aβ, tau, neurodegeneration, and cognitive pathology. TAKEAWAY: Plasma p-tau217/Aβ42 showed the highest accuracy in detecting PET Aβ positivity (area under the curve, 0.94), significantly outperforming all other biomarkers. All plasma biomarkers were significantly different between A+ and A− individuals, with plasma p-tau217/Aβ42 and p-tau217 showing the largest effect sizes (η 2 , 0.28 and 0.23, respectively). , 0.28 and 0.23, respectively). Plasma Aβ42/40 was highly sensitive to random variability, affecting its reliability in detecting Aβ pathology, particularly when the coefficient of variation exceeded 9% for PET or 16% for CSF classification. Longitudinal increases in plasma p-tau217 and p-tau217/Aβ42 best predicted future Aβ accumulation (CSF Aβ42/40 reduction: β, −0.44; P < .0001; PET Centiloid increase: β, 0.33; P < .0001). IN PRACTICE: "Fully automated immunoassay-based blood biomarkers offer significant diagnostic, prognostic, and monitoring capabilities for CU individuals at risk of AD [Alzheimer's disease] even in a relatively short time span," the authors of the study wrote. SOURCE: This study was led by Armand González-Escalante, Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain. It was published online on May 24, 2025, in eBioMedicine . LIMITATIONS: This study was limited by unmeasured factors such as lifestyle factors, occupational exposures, or genetic variants, which may still influence plasma biomarker levels and Aβ accumulation. Results from a middle-aged, at-risk cohort with low progression to mild cognitive impairment limited the generalisability to older populations. As a single-centre study, the results need to be replicated in larger, independent cohorts. DISCLOSURES: This study was funded by the European Research Council, ERA PerMed-ERA NET, and the Generalitat de Catalunya. Some authors reported receiving consultancy/speaker fees from several pharmaceutical organisations.
Yahoo
a day ago
- Yahoo
We're Oklahoma doctors. Here's the truth about vaccines.
The goal of medical science is to improve our quality of life. In the past century, relatively few things have more fully demonstrated this goal than the antiviral and antibacterial vaccines that have protected our most vulnerable populations. The World Health Organization (WHO) estimates that in the last 50 years, immunizations have saved the lives of over 150 million children. Almost nothing illustrates the transformative power of vaccination better than the 1955 arrival of Jonas Salk's polio vaccine. No longer was American society helpless before a seasonal plague of paralysis that claimed 15 to 20 thousand victims annually. Polio vaccines were followed by measles vaccines and then mumps, German measles and varicella vaccines. The scope of this blessing has continued to expand with immunizations for pneumococcus, meningococcus, rotavirus and other infectious diseases. And while these childhood vaccines have been overwhelming successes, society has forgotten the tragedies of past diseases and instead embraced new fears that threaten all the progress we've made. One of these fears is the unsupported link between vaccination and autism. Opinion: When autism is painted with a broad brush, it fuels stigma, discrimination It's understandable that the increasing number of cases of childhood autism, whether enhanced by more vigilance or expanded definitions, has begged for an explanation. Unfortunately, this desire for an answer has spawned some poorly executed medical studies. Notorious among these articles was the February 1998 paper published by Dr. Andrew Wakefield in The Lancet. Upon scrutiny, it was revealed that Dr. Wakefield had conflicts of interest that included serving as a clearing house for plaintiff attorneys while promoting his own alternative vaccine and manipulating the data to obtain the conclusions he desired. The Lancet later retracted the article, and Dr. Wakefield lost his medical license ― though not before lasting damage was done. In fact, despite 24 studies refuting the association between vaccines and autism, some individuals continue to embrace skepticism. The net result of this unfortunate tide of mistrust is that vaccination rates have begun to fall dramatically in some areas of the US, resulting in a loss of herd immunity. If measles resurrects itself through flagging vaccination rates, other afflictions from our past are sure to follow. It is only a matter of time before polio, mumps and other vaccine-preventable infections find their footing. While it is hard to predict exact numbers, it is easy to conclude that each case of serious illness or death from a preventable disease is a tragedy. The truth is that vaccines are safe, and the legitimate questions about vaccine-related autism or other harms can be answered. The truth is, public health is a team sport. If we can't play according to specific rules, loss is inevitable in what is anything but a game. Nevertheless, to win, we have to contain the disease. Even though many vaccines protect at rates greater than 90%, protection is not perfect if the disease is widespread. It will be difficult to change the minds of some. However, for those searching for the truth, the answers are available and as clear as good science can make them. The Oklahoma State Medical Association recommends that Oklahomans discuss any questions or concerns about vaccination with a pediatrician or other trusted physician. While there may be distrust of organizational expertise, it is our hope that faith in the doctor-patient relationship remains intact. The stakes couldn't be higher. Sumit Nanda, M.D., is a board-certified ophthalmologist with INTEGRIS Health in Oklahoma City. He is president of the Oklahoma State Medical Association. James Kirk, M.D., is an Oklahoma City-based infectious disease specialist with more than 40 years of expertise. This article originally appeared on Oklahoman: OK doctors like us know vaccines don't cause autism | Opinion
